Page last updated: 2024-12-10

3-(2-methoxyphenyl)-4-phenyl-1H-imidazole-2-thione

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID4962043
CHEMBL ID1487707
CHEBI ID123241

Synonyms (19)

Synonym
UNM000011095201
1-(2-methoxyphenyl)-5-phenyl-1h-imidazole-2-thiol
852388-86-4
EN300-12736
MLS001007615 ,
smr000384694
CHEBI:123241
UNM-0000306211
3-(2-methoxyphenyl)-4-phenyl-1h-imidazole-2-thione
HMS2684B16
AKOS008987412
AB00605786-02
CHEMBL1487707
bdbm33197
1-(2-methoxyphenyl)-5-phenyl-4-imidazoline-2-thione
cid_4962043
Q27212931
Z85921936
CS-0232504
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
1,3-dihydroimidazole-2-thionesA member of the class of imidazoles that is 1,3-dihydroimidazole-2-thione and its derivatives by substitution.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency19.90540.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency19.95260.631035.7641100.0000AID504339
phosphopantetheinyl transferaseBacillus subtilisPotency10.00000.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency17.35820.000811.382244.6684AID686978; AID686979
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency19.95260.707912.194339.8107AID720542
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency2.51190.011212.4002100.0000AID1030
hypothetical protein, conservedTrypanosoma bruceiPotency5.62340.223911.245135.4813AID624173
regulator of G-protein signaling 4Homo sapiens (human)Potency100.00000.531815.435837.6858AID504845
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency56.23410.707936.904389.1251AID504333
pyruvate kinaseLeishmania mexicana mexicanaPotency11.22020.398113.744731.6228AID1721; AID1722
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.89130.035520.977089.1251AID504332
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency4.22090.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency5.17350.004611.374133.4983AID624296
Endothelin receptor type BRattus norvegicus (Norway rat)Potency11.22020.562315.160931.6228AID1721
Endothelin-1 receptorRattus norvegicus (Norway rat)Potency11.22020.562315.160931.6228AID1721
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency8.49210.060110.745337.9330AID485367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
bcl-2-related protein A1 isoform 1Homo sapiens (human)EC50 (µMol)0.92001.23003.15506.5300AID1320; AID2080
Bcl-2-like protein 10Homo sapiens (human)EC50 (µMol)28.21001.46001.46001.4600AID1327; AID2077
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
apoptotic processBcl-2-like protein 10Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processBcl-2-like protein 10Homo sapiens (human)
spermatogenesisBcl-2-like protein 10Homo sapiens (human)
female gamete generationBcl-2-like protein 10Homo sapiens (human)
microtubule organizing center organizationBcl-2-like protein 10Homo sapiens (human)
negative regulation of apoptotic processBcl-2-like protein 10Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageBcl-2-like protein 10Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandBcl-2-like protein 10Homo sapiens (human)
release of cytochrome c from mitochondriaBcl-2-like protein 10Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
calcium ion bindingBcl-2-like protein 10Homo sapiens (human)
protein bindingBcl-2-like protein 10Homo sapiens (human)
caspase bindingBcl-2-like protein 10Homo sapiens (human)
BH domain bindingBcl-2-like protein 10Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
mitochondrionBcl-2-like protein 10Homo sapiens (human)
endoplasmic reticulumBcl-2-like protein 10Homo sapiens (human)
spindleBcl-2-like protein 10Homo sapiens (human)
cytosolBcl-2-like protein 10Homo sapiens (human)
membraneBcl-2-like protein 10Homo sapiens (human)
nuclear membraneBcl-2-like protein 10Homo sapiens (human)
mitochondria-associated endoplasmic reticulum membrane contact siteBcl-2-like protein 10Homo sapiens (human)
mitochondrial outer membraneBcl-2-like protein 10Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]